Treatment of Advanced Myelodysplastic Syndrome With Demethylating Agents: Azacitidine

Seminars in Hematology

Volumn 49, Issue 4, 2012, Pages 323-329

  Adès, Lionel ^a   Itzykson, Raphael ^a   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTIBIOTIC AGENT; ARSENIC DERIVATIVE; AZACITIDINE; CYTARABINE; DACOGENE; ENTINOSTAT; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; LEVOFLOXACIN; MOCETINOSTAT; PANOBINOSTAT; POSACONAZOLE; THALIDOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONSTIPATION; CYTOPENIA; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG WITHDRAWAL; HIGH RISK POPULATION; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; LEUKOPENIA; LUNG DISEASE; MALIGNANT TRANSFORMATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 84867607380     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.09.002     Document Type: Article

References (52)

1. Gondek L.P., Tiu R., O'Keefe C.L., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
2. Stresemann C., Bokelmann I., Mahlknecht U., Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008, 7:2998-3005.
3. Quesnel B., Guillerm G., Vereecque R., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91:2985-2990.
4. Qian J., Yao D.M., Lin J., et al. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. Int J Lab Hematol 2010, 32:74-81.
5. Wu S.J., Yao M., Chou W.C., et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 2006, 135:317-323.
6. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006, 76:23-32.
7. Papaemmanuil E., Cazzola M., Boultwood J., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
8. Yoshida K., Sanada M., Shiraishi Y., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
9. Alexander R., Beggs J.D. Cross-talk in transcription, splicing and chromatin: who makes the first call?. Biochem Soc Trans 2010, 38:1251-1256.
10. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
11. Hollenbach P.W., Nguyen A.N., Brady H., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010, 5:e9001.
12. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
13. Tsai H.C., Li H., Van Neste L., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21:430-446.
14. Aimiuwu J., Wang H., Chen P., et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 2012, 119:5229-5238.
15. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
16. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
17. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:2232.
18. Silverman L.R., Fenaux P., Mufti G.J., et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011, 117:2697-2702.
19. Seymour J.F., Fenaux P., Silverman L.R., et al. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010, 76:218-227.
20. Itzykson R., Thepot S., Quesnel B., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.
21. Santini V., Fenaux P., Mufti G.J., et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010, 85:130-138.
22. Itzykson R., Thepot S., Quesnel B., et al. Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood 2012, 119:6172-6173.
23. van der Helm L.H., Alhan C., Wijermans P.W., et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011, 155:599-606.
24. Mufti G.J., Gore S.D., Santini V., et al. Influence of karyotype on overall survival in patients with higher-risk myelodysplastic syndrome treated with azacitidine or a conventional care regimen. Blood (ASH Annual Meeting) 2009, 14:1755.
25. Breccia M., Salaroli A., Loglisci G., et al. MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine. Haematologica 2012, 97:e2.
26. Shen L., Kantarjian H., Guo Y., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28:605-613.
27. Follo M.Y., Russo D., Finelli C., et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia 2012, 26:943-950.
28. Itzykson R., Kosmider O., Cluzeau T., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25:1147-1152.
29. Traina F., Jankowska A.M., Visconte V., et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. Blood (ASH Annual Meeting) 2011, 116.
30. Kulasekararaj A.G., Mohamedali A.M., Smith A.E., et al. Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients. ASH Annual Meeting Abstracts 2010, 116:125.
31. Santini V., Fenaux P., Mufti G.J., et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010, 85:130-138.
32. Itzykson R., Thepot S., Achour B., et al. Azacytidine (AZA) in MDS (including RAEB-t and CMML) in patients (pts) >= 80 years: results of the French ATU program. ASH Annual Meeting Abstracts 2009, 114:1773.
33. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27:1850-1856.
34. Dimicoli S., Jabbour E., Borthakur G., et al. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 2012, 87:127-129.
35. Giles F., Fischer T., Cortes J., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006, 12:4628-4635.
36. Garcia-Manero G., Yang H., Bueso-Ramos C., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
37. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
38. Soriano A.O., Yang H., Faderl S., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
39. Raffoux E., Cras A., Recher C., et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010, 1:34-42.
40. Silverman L.R., Verma A., Odchimar-Reissig R., et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol 2008, 26(Suppl). abstract 7000.
41. Sekeres M.A., List A.F., Cuthbertson D., et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2011, 28:2253-2258.
42. Itzykson R., Thepot1 S., Beyne-Rauzy O., et al. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?. Leuk Res 2012, 36:397-400.
43. Thepot S., Itzykson R., Seegers V., et al. Azacytidine (AZA) as first line therapy in AML: results of the French ATU Program. ASH Annual Meeting Abstracts 2009, 114(22):843.
44. Thepot S., Itzykson R., Seegers V., et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2011, 116:3735-3742.
45. Fadlallah J., Bally C., Quesnel B., et al. AZA in the treatment of therapy related MDS and AML (tMDS/AML): a report on 60 patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM). ASH Annual Meeting Abstracts 2010, 116:2911.
46. Klimek V.M., Fircanis S., Maslak P., et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008, 14:826-832.
47. Wijermans P.W., Ruter B., Baer M.R., et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008, 32:587-591.
48. Aribi A., Borthakur G., Ravandi F., et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007, 109:713-717.
49. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
50. Braun T., Itzykson R., Renneville A., et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011, 118:3824-3831.
51. Costa R., Abdulhaq H., Haq B., et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011, 117:2690-2696.
52. Ades L., Sekeres M.A., Wolfromm A., et al. Prognostic factors of response and survival in CMML patients treated with azacitidine (AZA). ASH Annual Meeting Abstracts 2011, 118:1726.